Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics | Synapse
March 3, 2026
Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics
BW
Bruce A. Warden
Oregon Health & Science University
PD
Paul Barton Duell
JB
John D. Bucheit
Virginia Commonwealth University
Ver todo
Puntos clave
GLP-1 receptor agonists significantly enhance weight management and appetite control in patients with obesity.
A meta-analysis of multiple trials reveals a reduction of up to 10% in body weight with GLP-1 therapies.
Observational analysis focused on pharmacotherapy interventions in managing obesity-related metabolic pathways.
These findings support the potential of GLP-1 receptor agonists as a key therapeutic strategy for obesity treatment.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Warden et al. (Thu,) studied this question.
synapsesocial.com/papers/69a759e3c6e9836116a1f46a
https://doi.org/https://doi.org/10.1016/j.jacl.2025.11.013